ATAI Investor Presentation Deck

SUMMARY OWNERSHIP 100%¹ PRODUCT PHARMA- COLOGY PRODUCT FEATURES INDICATIONS CURRENT STATUS INTELLECTUAL PROPERTY HIGHLIGHT Dimethyltryptamine (DMT) in a buccal transmucosal film (VLS-01), DMT is the active psychedelic moiety in Ayahuasca 5-HT2A-R agonist Rapid onset, sustained efficacy after single dose, short duration of psychedelic effect (~30 to 45 minutes) Primary: Treatment Resistant Depression Potential: Eating Disorders, Substance Use Disorders Phase 1 clinical trial initiated in mid-'22 Filed provisional on formulations of DMT VLS-01 is designed to have an improved duration of psychedelic effect while improving tolerability VLS-01 may increase patient accessibility by reducing patient and clinic time commitment PRIOR EVIDENCE IN HUMANS (THIRD PARTY STUDY²) MADRS Score Double-blind, randomized placebo-controlled trial with Ayahuasca in 29 patients with TRD 45 40 35 30 25 20 15 10 5 0 HA Baseline p<.05 Day 1 p<.05 Day 2 HH p=.0001 Day 7 Note: MADRS: Montgomery-Asberg Depression Rate Scale. 1. Unless otherwise indicated herein, ownership percentage based on ownership of securities with voting rights as of June 30th, 2022 2. Palhano-Fontes et al. "Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression", Psychol Med (2019) Ayahuasca 13 Placebo

View entire presentation